

Pursues collaboration based growth

14 June 2010 | News


image not found or type unknown



16

Ju

sys




Head:

Shyam S Bhartia (Chairman & MD)

Business:

Integrated pharma industry player with focus on CRAMS and DDDS



Startup Year:

1978

Address:

1A, Sector 16A, Noida-201301,
Uttar Pradesh

Tel:

+91-120-2516601-11

Fax:

+91-120-2516628-30

Website:

www.jubl.com

Jubilant Organosys focuses on the pharmaceutical value chain for products and services such as exclusive synthesis, contract manufacturing, proprietary products, active pharmaceutical ingredients, generic dosage forms, drug discovery services, drug development services, chemistry services, clinical research services, steriles, non-

With a revenue of Rs 249 crore in FY 2009-10 from the services business, Jubilant has reported a mild growth over FY 2008-09 when its revenue stood at Rs 242 crore. This growth is because of its efforts to accelerate global drug discovery by concentrating on flexible and hybrid platform of innovative discovery chemistry, biology and insilico services. Besides going for collaborations over the years, the company has also made n market.

The company has five subsidiaries in India that include Jubilant Biosys for discovery informatics and drug discovery services; Jubilant Chemsys for medicinal chemistry; Clinsys Clinical Research for clinical research and bioavailability or bio-equivalence studies; Jubilant First Trust Healthcare for high-quality healthcare services and Specialty tinuous vapor phase halogenations reaction.

In May 2009, Jubilant signed a research collaboration agreement with AstraZeneca, with focus on delivering novel drug candidates into its preclinical pipeline. In June 2009, Jubilant Biosys has entered into a discovery and development collaboration with Endo Pharmaceuticals, a US-based pharma company to develop a portfolio of targets in the

In November 2009, Jubilant Organosys and University of Alabama at Birmingham (UAB) entered into a drug discovery joint venture to focus on leveraging their collective innovation and enabling technologies in the areas of oncology, metabolic and infectious

In December 2009, Jubilant and Eli Lilly extended their drug discovery collaboration to preclinical molecules and their development through phase-II clinical trials for five years. The joint venture based out of Bangalore came into existence in October 2008. Lilly and Jubilant had also established a joint venture, Vanthys Pharmaceuticals, for early stage

On December 16, 2009, Jubilant strengthened its global leadership position in vitamin B3 by setting up new 10,000 TPA Niacinamide plant expected to be ready by the end of 2010. Jubilant is currently ranked amongst the top three manufacturers of niacin and niacinamide (vitamin B3) worldwide and is also the largest producer of beta picoline, a ure of vitamin B3, globally.

In 2008, Jubilant signed several R&D deals. In July 2008, Jubilant Biosys, Bangalore, and Amgen, California, announced a drug discovery partnership to develop a portfolio of novel drugs in new target areas across multiple therapeutic areas.